Evidence map›Paper›PMID 21723612›Full record

ArticleMolecular immunology2011

In vitro C3 deposition on Cryptococcus capsule occurs via multiple complement activation pathways.

Kileen L Mershon-Shier, Alex Vasuthasawat, Kazue Takahashi, Sherie L Morrison, David O Beenhouwer

Abstract read
In one paragraph

Article in Molecular immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Mechanisms of fungal dissemination.Cellular and molecular life sciences : CMLS · 2021
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kileen L Mershon-ShierDepartment of Microbiology, Immunology, and Molecular Genetics and the Molecular Biology Institute, University of California, Los Angeles, CA, United States.
Alex Vasuthasawat
Kazue Takahashi
Sherie L Morrison
David O Beenhouwer

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTON, PETER A · 1991 to 2018
$39.9M
Antibody cytokine fusion proteins against Cryptococcus neoformansR01AI071025 · NIAID · BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE · PI BEENHOUWER, DAVID OWEN · 2008 to 2012
$1.6M
MECHANISM OF ANTIBODY PROTECTION AGAINST C. NEOFORMANSR01AI051415 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORRISON, SHERIE L · 2003 to 2007
$1.5M
NCI NIH HHS P30 CA016042NIAID NIH HHS P30 AI028697NIAID NIH HHS R01 AI051415NIAID NIH HHS R01 AI071025
6 · The paper itself

Abstract

Complement can be activated via three pathways: classical, alternative, and lectin. Cryptococcus gattii and Cryptococcus neoformans are closely related fungal pathogens possessing a polysaccharide capsule composed mainly of glucuronoxylomannan (GXM), which serves as a site for complement activation and deposition of complement components. We determined C3 deposition on Cryptococcus spp. by flow cytometry and confocal microscopy after incubation with serum from C57BL/6J mice as well as mice deficient in complement components C4, C3, factor B, and mannose binding lectin (MBL). C. gattii and C. neoformans activate complement in EGTA-treated serum indicating that they can activate the alternative pathway. However, complement activation was seen with factor B(-/-) serum suggesting activation could also take place in the absence of a functional alternative pathway. Furthermore, we uncovered a role for C4 in the alternative pathway activation by Cryptococcus spp. We also identified an unexpected and complex role for MBL in complement activation by Cryptococcus spp. No complement activation occurred in the absence of MBL-A and -C proteins although activation took place when the lectin binding activity of MBL was disrupted by calcium chelation. In addition, alternative pathway activation by C. neoformans required both MBL-A and -C, while either MBL-A or -C was sufficient for alternative pathway activation by C. gattii. Thus, complement activation by Cryptococcus spp. can take place through multiple pathways and complement activation via the alternative pathway requires the presence of C4 and MBL proteins.

Indexed as

AnimalsAntigens, FungalCell SeparationComplement C3Complement C4Complement Pathway, AlternativeComplement Pathway, ClassicalComplement Pathway, Mannose-Binding LectinCryptococcusFlow CytometryMannose-Binding LectinMiceMice, Inbred C57BLMice, KnockoutMicroscopy, ConfocalPolysaccharidesAntigens, FungalComplement C3Complement C4glucuronoxylomannanMannose-Binding LectinPolysaccharides

Identifiers

PMID21723612
PMCPMC3163710

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.